Education
About Us
Working with TipRanks
Follow Us
NeurAxis, Inc. (NRXS)
:NRXS
Earnings Data
Report Date
Sep 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.42Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 99.50%
|Next Earnings Date:Sep 18, 2025
Earnings Call Sentiment|Neutral
NeurAxis demonstrated strong revenue growth and strategic progress with insurance coverage and regulatory milestones. However, challenges remain with insurance coverage and financial impacts due to legal settlements. The overall sentiment is cautiously optimistic, with significant achievements balancing the existing challenges.Company Guidance
During NeurAxis' First Quarter 2025 Results and Update Call, the company provided guidance indicating strong financial performance and promising growth prospects. The CEO, Brian Carrico, highlighted a significant revenue trajectory with consistent double-digit growth over the past three quarters, including a 39% increase in Q1 2025. The company is focused on expanding insurance policy coverage, which has grown from 4 million to 51 million covered lives, and anticipates further revenue acceleration upon the implementation of the Category I CPT code effective January 1, 2026. NeurAxis also achieved an 84.4% gross margin this quarter, despite higher manufacturing costs, and aims for cash flow breakeven by leveraging strong data and academic society endorsements. Additionally, the FDA clearance for their RED device and expansion of the IB-Stim label are expected to significantly broaden market opportunities. The CFO, Tim Henrichs, noted an operating loss improvement when excluding a one-time legal settlement, and reaffirmed the company's strategic focus on cost management and sales growth to achieve profitability.Consistent Revenue Growth
NeurAxis achieved a 39% increase in revenue in Q1 2025 compared to Q1 2024, marking the third consecutive quarter of double-digit growth.
Expansion of Insurance Coverage
The company increased its covered lives from 4 million to 51 million over the past year.
Category I CPT Code Achievement
NeurAxis received a Category I CPT code, effective January 1, 2026, expected to facilitate easier billing and increase revenue.
FDA Approvals and Product Expansion
Expanded IB-Stim label to treat patients aged 8 to 21, and received FDA clearance for RED, a rectal expulsion device.
High Gross Margin
Despite challenges, the company maintained a gross margin of 84.4% in Q1 2025.
NRXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NRXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $2.00 | $2.32 | +16.00% |
Mar 20, 2025 | $2.29 | $2.27 | -0.87% |
Nov 12, 2024 | $2.50 | $3.16 | +26.40% |
Aug 09, 2024 | $2.85 | $3.11 | +9.12% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NeurAxis, Inc. (NRXS) report earnings?
NeurAxis, Inc. (NRXS) is schdueled to report earning on Sep 18, 2025, TBA Not Confirmed.
What is NeurAxis, Inc. (NRXS) earnings time?
NeurAxis, Inc. (NRXS) earnings time is at Sep 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NRXS EPS forecast?
NRXS EPS forecast for the fiscal quarter 2025 (Q2) is -0.23.